In this study we investigated in vitro and in vivo effects of propofol in malignant hyperthermia susceptible (MHS) patients in order to assess the safety of propofol infusion as a non-triggering anaesthetic technique for diagnostic and therapeutic procedures. In vitro, human MHS muscle samples were exposed to propofol and changes in (a) baseline tension and (b) contracture tension on exposure to halothane and caffeine were measured.
Palmerston North Hospital is the only facility in New Zealand providing a diagnostic muscle biopsy service for malignant hyperthermia (MH). Possible MH susceptible (MHS) patients present frequently for biopsy or for therapeutic surgical procedures.
A simple, quick and reliable technique for muscle biopsy anaesthesia would be a general anaesthetic with spontaneous ventilation and rapid recovery characteristics. Propofol infusions, because of their proven ability to replace volatile anaesthetic agents in spontaneous ventilation techniques and their rapid recovery characteristics, seemed an ideal option. 1 However, propofol had not undergone sufficient investigation to demonstrate its safety in patients with MH. When the study was commenced, published experience was limited to two MHS swine and two MHS human muscle samples in vitro, 2 two series of MHS swine anaesthetised with propofol,3,4 and two MHS humans mentioned in case reports. 5 ,6 Propofol use in four MHS humans was reported in one of the swine anaesthesia studies, but no details of anaesthetic technique or monitoring were included. 4 We decided to investigate further the response of human MHS muscle in vitro, and the response of human MHS patients to bolus doses of propofol prior to conducting studies on the safety of propofol infusion anaesthesia in MHS individuals.
METHODS AND PATIENTS (a) In vitro testing of propofol and human MHS muscle samples.
All muscle samples were obtained from the medial quadriceps muscle of patients undergoing diagnostic muscle biopsy. Anaesthesia was produced by using regional or general techniques, a volatile-agent-free machine and non-triggering drugs. Propofol was not used as part of these anaesthetics. Specimens were transported to the laboratory without delay in Kreb's-Ringer buffer (KRB) and testing completed within five hours of biopsy excision, in accordance with the protocol of the European MH Group, 7 but with the omission of a dynamic test.
Fascicles were carefully dissected and undue stretching avoided. For each test, a fresh fascicle was suspended in a 40 ml testing bath of KRB at 37°C through which was continuously bubbled 5% CO 2 in oxygen. The initial tension on the fascicle was adjusted to give maximum twitch height, continuing sample viability demonstrated by the > 0.4 g twitch response to electrical stimulation at 0.2 Hz. Concentrations of halothane or caffeine in the bath were increased incrementally and changes in baseline tension (contracture) measured with a strain gauge. Halothane concentrations in the bath, measured by gas chromatography, conformed to the requirements of the European protocol at 0.43 mmol/l when the output of the vapouriser was 2%.
Diagnostic criteria were as follows: MHS (susceptible) > 0.2 g contracture to both 2% halothane and 2 mM caffeine; MHN (normal) < 0.2 g contracture to both 2% halothane and 2 mM caffeine; MHE (equivocal) > 0.2 g contracture to 2% halothane or 2 mM caffeine.
(i) Effects of propofo/ on baseline tension. Propofol was diluted 1:25 (400 ).Lg/ml) in KRB at 37°C immediately before use. A fresh fascicle was suspended in the bath as previously described and a stable baseline tension achieved. Aliquots of diluted propofol were added to increment the final concentration through 4, 8, 12, 16, 32 and 64 ).Lg/ ml. Baseline tension was observed over the subsequent ten minutes. Six fascicles from four different MHS patients were tested in this way.
(ii) Effects of propofo/ on contracture development.
Propofol was diluted as in (i). A fresh fascicle was placed in the organ bath and propofol was added to the bath at twenty-second intervals to increment the final concentration through 4, 8, 12, 16 and 20 ).Lg/ml. The first aliquot of propofol was added when the baseline tension started to increase after the triggering concentration of either halothane or caffeine had been added. When all the propofol had been added the test proceeded in the normal manner with additional halothane or caffeine. A total of ten MHS patients muscle biopsy samples were tested in this way. The tension developed by the samples exposed to propofol was then compared with that developed by the first sample from the same patient.
Ten control samples for both the halothane and caffeine tests came from thirteen patients; seven MHS and six MHE. These samples were processed identically but without the addition of propofol to either the first or second sample during the halothane or caffeine testing. Following approval of the study protocol by the hospital Ethics Committee, ten MHS individuals, ASA I or 11, aged between 16 and 50 years, gave consent to participate. The diagnosis of susceptibility was made using the criteria for the caffeine/halothane contracture test as previously described. All patients were undergoing diagnostic muscle biopsy when they were anaesthetised using propofol as an induction agent, and inclusion in the study results was dependent upon an MHS biopsy result.
Following premedication with midazolam 7.5-15 mg and metoclopramide 10 mg orally one hour preoperatively, the patients were brought to theatre and given 30 ml 0.3 mol sodium citrate. Monitoring was commenced with ECG, indirect BP, pulse oximetry and an intravenous infusion of 0.9% NaCl commenced. Anaesthesia was induced with propofol 2.5 mg/kg, vecuronium 0.08 mg/kg, alfentanil 10 ).Lg/kg and maintained with nitrous oxide/oxygen and incremental boluses of alfentanil. Additional intraoperative monitoring included capnography, peripheral nerve stimulator, continuous rectal temperature and baseline arterial blood gas analysis taken immediately following induction. IPPY was adjusted to produce normocapnoea and then was not altered during the anaesthetic. At the end of the operation, muscle relaxants were reversed with atropine 1.2 mg and neostigmine 2.5 mg. All patients were observed in the Recovery Room for four hours with continuous ECG, pulse oximetry and temperature measurement. Blood pressure measurements were taken intermittently and blood gas analysis was repeated thirty minutes after arrival in the Recovery Room (approximately one hour after induction of anaesthesia). Following the patients' return to the surgical ward, hourly temperature and pulse rate were recorded overnight.
(b) (ii) Induction and maintenance of anaesthesia with propofol in MHS patients.
Consent for propofol infusion based anaesthesia studies was then obtained from the Ethics Committee. Five patients were recruited as in (b) (i) before the study was terminated as a result of work published elsewhere. 8 Premedication and preinduction monitoring was identical to that used during the propofol induction studies. Morphine 0.1 mg/kg and droperidol 0.05 mg/kg IY were followed by a 3 mg/kg bolus of propofol to induce anaesthesia. After placement of a laryngeal mask airway, anaesthesia was maintained with a 10 mg/ kg/hr propofol infusion for the first ten minutes, 8 mg/kg/hr for the next ten minutes, and 6 mg/kg/hr thereafter. Spontaneous ventilation was achieved easily in all five patients. Intraoperative monitoring differed only by the omission of the peripheral nerve stimulator. Recovery procedures were also identical apart from arterial blood gas samples being taken at one and two hours after induction of anaesthesia.
RESULTS

(a) In vitro testing of MHS muscle samples. (i) Changes in baseline tension of MHS muscle samples upon exposure to propofol.
No change in baseline tension> 0.1 g occurred in response to the addition of propofol in any specimen at any of the concentrations achieved. (ii) Changes in contracture development upon exposure to halothane or caffeine following addition of propofol.
Tests on the second specimens, when propofol had been added, in most cases showed a smaller increase in tension compared with the tension achieved with the first (MHS diagnostic) specimen. A similar pattern was seen in the control paired samples. The percentage tension change between the first and second specimens in the pairing exposed to propofol is not significantly different from that recorded in the controls (Student's t test, P < 0.05 significant). Lower peak tensions in second and subsequent specimens during muscle biopsy testing are not uncommon in our laboratory. (b) In vivo (i) Induction of anaesthesia in ten MHS patients with 2.5 mglkg ofpropofol.
During maintenance of anaesthesia, no patient developed a significant increase in end-tidal C02 levels in the face of a stable controlled ventilation pattern. No patient developed a combination of tachycardia, increasing temperature, and increasing base deficit consistent with the development of MH during anaesthesia or their subsequent four-hour stay in the Recovery Room. (ii) Induction and maintenance of anaesthesia with propofol in five MHS patients.
No patient developed signs consistent with the development of MH during anaesthesia or recovery. Use of the laryngeal mask airway allowed intraoperative monitoring of both respiratory rate and end-tidal C02 tension with neither of these increasing significantly in any patient during anaesthesia.
DISCUSSION
The final part of the study was stopped after publication of a report of propofol infusion based anaesthesia in nine muscle biopsy positive MHS patients without signs of MH triggering. 8 Our results and all previously published work are in agreement that propofol has not been shown to trigger an MH response in vitro nor following induction and maintenance of anaesthesia with propofol.
In vitro: In vitro testing of the response of human skeletal muscle to propofol had been very limited. In MHN muscle samples, propofol 100 ).1g1ml had been shown to increase the static caffeine threshold from 4 mM to 8 mM caffeine 9 . Denborough Anaesthesia and Intensive Care. Vol. 20, No. 2, May, 1992 reported two MHS human muscle samples and two MHS swine muscle samples that developed contractures with halothane and caffeine but not with propofo1. 2 However, the propofol concentrations achieved in the organ bath were not clearly stated.
Using propofol infusions to supplement a lorazepam premedication, nitrous oxide/oxygen, spontaneous ventilation, no-opiate anaesthetic technique, an ED95 of 348 ).1g/kg/min was necessary, with an Effective Concentration 95 of 5.92 ).1g1ml, in patients presenting for body surface surgery. 10 To be relevant to clinical practice, in vitro research should reflect that practice as much as possible, hence the propofol concentrations we studied included the clinically useful range, i.e, up to 8 ).1g1ml.
In our in vitro series, we were concerned with two questions, 1. Does propofol trigger an MH response?
The results from the six human MHS samples using concentrations ranging from 4 to 64 ).1g1ml confirm previous work and show no triggering effect in the range of propofol concentrations likely to be achieved in clinical practice.
Does propofol decrease the sensitivity of the muscle biopsy test?
Addition of propofol to the organ bath, in our series of human MHS samples, did not produce a significant change in tension development. In our opinion the decrease in the contracture tension recorded with most second specimens is due to specimen deterioration and not to a specific effect of propofol. We conclude that propofol does not affect the sensitivity ofthe test at concentrations up to 20 ).1g1ml, which is considerably higher than the plasma concentrations likely to be achieved with propofol infusion anaesthesia. In vivo: The use of propofol infusion anaesthesia, including the patients in this study, has now been documented in seventeen 5 ,6,8,ll MHS patients without any sign of MH triggering.
All studies involving propofol and MHS patients have produced results that consistently show no MH triggering effect. We believe that propofol should now be recognised as a 'safe' drug in the anaesthetic management of MHS individuals and that it can be recommended for both spontaneous and controlled ventilation techniques.
